First Time Loading...

Editas Medicine Inc
NASDAQ:EDIT

Watchlist Manager
Editas Medicine Inc Logo
Editas Medicine Inc
NASDAQ:EDIT
Watchlist
Price: 5.55 USD -1.07% Market Closed
Updated: Apr 19, 2024

Operating Margin
Editas Medicine Inc

-216.6%
Current
-660%
Average
-7.9%
Industry
Negative for the last year
-216.6%
Negative average
-660%
Better than average
Worse than industry value

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-216.6%
=
Operating Profit
-169.2m
/
Revenue
78.1m

Operating Margin Across Competitors

Operating Margin Comparison
Editas Medicine Inc Competitors

Country Company Market Cap Operating
Margin
US
Editas Medicine Inc
NASDAQ:EDIT
453.4m USD
-217%
US
Abbvie Inc
NYSE:ABBV
290.8B USD
30%
US
Amgen Inc
NASDAQ:AMGN
140.7B USD
29%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
101.4B USD
39%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
97.8B USD
32%
AU
CSL Ltd
ASX:CSL
131.1B AUD
26%
US
Gilead Sciences Inc
NASDAQ:GILD
82.4B USD
30%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
-33%
US
Moderna Inc
NASDAQ:MRNA
39B USD
-62%
US
Biogen Inc
NASDAQ:BIIB
27.6B USD
21%
IE
Horizon Therapeutics PLC
NASDAQ:HZNP
26.6B USD
16%
Editas Medicine Inc
NASDAQ:EDIT
Country US
Market Cap 453.4m USD
Operating Margin
-217%
Abbvie Inc
NYSE:ABBV
Country US
Market Cap 290.8B USD
Operating Margin
30%
Amgen Inc
NASDAQ:AMGN
Country US
Market Cap 140.7B USD
Operating Margin
29%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Country US
Market Cap 101.4B USD
Operating Margin
39%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Country US
Market Cap 97.8B USD
Operating Margin
32%
CSL Ltd
ASX:CSL
Country AU
Market Cap 131.1B AUD
Operating Margin
26%
Gilead Sciences Inc
NASDAQ:GILD
Country US
Market Cap 82.4B USD
Operating Margin
30%
Seagen Inc
NASDAQ:SGEN
Country US
Market Cap 43.1B USD
Operating Margin
-33%
Moderna Inc
NASDAQ:MRNA
Country US
Market Cap 39B USD
Operating Margin
-62%
Biogen Inc
NASDAQ:BIIB
Country US
Market Cap 27.6B USD
Operating Margin
21%
Horizon Therapeutics PLC
NASDAQ:HZNP
Country IE
Market Cap 26.6B USD
Operating Margin
16%

Profitability Report

View the profitability report to see the full profitability analysis for Editas Medicine Inc.

Full Profitability Report

See Also

Summary
EDIT intrinsic value, competitors valuation, and company profile.
DCF Valuation
EDIT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
EDIT stock valuation using valuation multiples.
Wall Street Estimates
EDIT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
EDIT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-216.6%
=
Operating Profit
-169.2m
/
Revenue
78.1m
What is the Operating Margin of Editas Medicine Inc?

Based on Editas Medicine Inc's most recent financial statements, the company has Operating Margin of -216.6%.

ALPHA SPREAD
Join more than 129,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.